33 Results for "

Ileal

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "Ileal" in MCE Product Catalog:

8
nor-Binaltorphimine
nor-Binaltorphimine
0 Images
8 Publications Verification
Cat. No.: HY-117040
CAS No.: 105618-26-6
Purity:  98.70%
Synonyms: Norbinaltorphimine; NorBNI
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the κ-opioid receptor. nor-Binaltorphimine blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain .
4
Odevixibat
Odevixibat
0 Images
4 Cited Publications
Cat. No.: HY-109120
CAS No.: 501692-44-0
Purity:  99.92%
Synonyms: A4250
Target:  

Apical Sodium-Dependent Bile Acid Transporter

Research Areas:  

Metabolic Disease

Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
1
Rebaudioside D
Rebaudioside D
0 Images
1 Cited Publications
Cat. No.: HY-N0468
CAS No.: 63279-13-0
Category:  

other families Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Food Research

Target:  

FXR Acetyl-CoA Carboxylase

Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
1
Astressin 2B TFA
Astressin 2B TFA
0 Images
1 Cited Publications
Cat. No.: HY-P1108A
Target:  

CRFR

Research Areas:  

Neurological Disease Inflammation/Immunology

Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
Maralixibat chloride
Maralixibat chloride
0 Images
Cat. No.: HY-16747
CAS No.: 228113-66-4
Synonyms: SHP625 chloride; LUM001 chloride; Lopixibat chloride
Target:  

Apical Sodium-Dependent Bile Acid Transporter

Research Areas:  

Metabolic Disease

Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
Lipopolysaccharides, from E. coli O127:B8
Lipopolysaccharides, from E. coli O127:B8
0 Images
Cat. No.: HY-D1056A2
Synonyms: LPS, from Escherichia coli (O127:B8)
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Guvacoline hydrochloride
Guvacoline hydrochloride
0 Images
Cat. No.: HY-N5016
CAS No.: 6197-39-3
Category:  

Cardiovascular Disease Alkaloids Pyridine Alkaloids Plants Palmae Areca triandra Roxb. Disease Research Fields

Target:  

mAChR

Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors .
Guvacoline hydrobromide
Guvacoline hydrobromide
0 Images
Cat. No.: HY-116490
CAS No.: 17210-51-4
Target:  

mAChR

Research Areas:  

Cardiovascular Disease

Guvacoline hydrobromide, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal mAChR .
264W94
264W94
0 Images
Cat. No.: HY-19264
CAS No.: 178961-24-5
Target:  

Apical Sodium-Dependent Bile Acid Transporter

Research Areas:  

Metabolic Disease

264W94 is a potent ileal bile acid transporter (IBAT) inhibitor and a new cholesterol lowering agent. 264W94 has CYP7A1 induction, and antilipemic action .
A71378
A71378
0 Images
Cat. No.: HY-111918
CAS No.: 127902-33-4
Target:  

Cholecystokinin Receptor

Research Areas:  

Metabolic Disease

A71378 is a selectivity CCK-A receptor agonist the IC50 values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC50 = 0.16 nM) and ileal muscle contraction (EC50 = 3.7 nM) .
LY53857
LY53857
0 Images
Cat. No.: HY-116680
CAS No.: 60634-51-7
Target:  

5-HT Receptor

Research Areas:  

Cardiovascular Disease Neurological Disease

LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
BTM-1042
BTM-1042
0 Images
Cat. No.: HY-136634
CAS No.: 72293-40-4
Target:  

mAChR

Research Areas:  

Others

BTM-1042 is a newly synthesized compound with antispasmodic effects. It can inhibit the twitch reaction of the guinea pig ileum under electrical stimulation and is not affected by naloxone. It has similar effects to atropine and can block muscarinic receptors, but has less effect on other types of receptors. BTM-1042 also has an inhibitory effect on the ileal reaction caused by nicotine and 5-hydroxytryptamine. BTM-1042 showed a dose-dependent inhibitory effect on the spontaneous movement of the rabbit stomach. In general, BTM-1042 is a agent with a strong antispasmodic effect.
Rebaudioside D (Standard)
Rebaudioside D (Standard)
0 Images
Cat. No.: HY-N0468R
CAS No.: 63279-13-0
Category:  

other families Terpenoids Diterpenoids Plants

Target:  

Reference Standards Acetyl-CoA Carboxylase FXR

Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
Chromogranin A (324-337), human
Chromogranin A (324-337), human
0 Images
Cat. No.: HY-P3826
CAS No.: 115136-18-0
Target:  

Peptides

Research Areas:  

Neurological Disease

Chromogranin A (324-337), human is a peptide fragment of chromogranin A, it can be isolated from human ileal carcinoid tumor. Chromogranin A is a soluble glycoprotein stored with hormones and neuropeptides in secretory granules of most (neuro)endocrine cells and neurons, and it is also a plasma marker of neuroendocrine tumors .
S-8921
S-8921
0 Images
Cat. No.: HY-19298
CAS No.: 151165-96-7
Target:  

Apical Sodium-Dependent Bile Acid Transporter

Research Areas:  

Metabolic Disease

S-8921 is an ileal Na +/bile acid cotransporter (IBAT) inhibitor.
L-687306
L-687306
0 Images
Cat. No.: HY-120418
CAS No.: 133444-98-1
Target:  

mAChR

Research Areas:  

Others

L-687306 is a high affinity muscarinic M1 receptor partial agonist with activity as a partial agonist of M1 receptors in rat ganglia and as a high affinity competitive antagonist at guinea pig cardiac M2 and ileal M3 muscarinic receptors, useful for studying the receptor reserve of muscarinic receptors.
Odevixibat (Standard)
Odevixibat (Standard)
0 Images
Cat. No.: HY-109120R
CAS No.: 501692-44-0
Synonyms: A4250 (Standard)
Target:  

Apical Sodium-Dependent Bile Acid Transporter Reference Standards

Research Areas:  

Metabolic Disease

Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
Odevixibat-d5
Odevixibat-d5
0 Images
Cat. No.: HY-109120S
Synonyms: A4250-d5
Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
Odevixibat-13C6
Odevixibat-13C6
0 Images
Cat. No.: HY-109120S1
Synonyms: A4250-13C6
Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
Terodiline hydrochloride
Terodiline hydrochloride
0 Images
Cat. No.: HY-16489A
CAS No.: 7082-21-5
Target:  

mAChR Calcium Channel

Research Areas:  

Neurological Disease

Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with Kbs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca 2+ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence .
Assay Types